Our Pipeline

Enabling durable treatment options in oncology

We are building a pipeline of uniquely assembled, highly stable ADCs by leveraging proprietary conjugation, linker and payload technologies that enable us to utilize previously inaccessible targeting molecules and novel payloads. We are currently advancing two proprietary lead candidates with first-in-class potential in solid tumors targeting the most deadliest cancers globally. Our goal is to consolidate the knowledge gained over the last 20 years and translating it into meaningful therapeutic benefits to broaden the treatment horizon of ADCs.

Proprietary programs

Program
Discovery
Preclinical
Phase I
TUB-030targeting 5T4
Discovery
Preclinical
Phase I
multiple solid cancers
TUB-030

TUB-030 is directed against the cancer antigen 5T4, expressed in a wide range of solid tumor indications. It is using Tubulis´proprietary P5 conjugation chemistry and shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index

TUB-040targeting Napi2b
Discovery
Preclinical
Phase I
ovarian, NSCLC
TUB-040

TUB-040 is a novel Napi2b-targeting ADC based on Tubulis´ proprietary P5 conjugation technology und its Tubutecan payload platform. Napi2b is a well-characterized target in ovarian and lung cancer. TUB-040 is optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

TUB-050target undisclosed
Discovery
Preclinical
Phase I
solid cancers
TUB-050
Detailed Content Here
TUB-060target undisclosed
Discovery
Preclinical
Phase I
solid cancers
TUB-060
Detailed Content Here

Partnered programs

Program
Discovery
Preclinical
Phase I
BMSmultitarget collaboration
Discovery
Preclinical
Phase I
BMS
Detailed Content Here
TUB-010/TEQ102targeting CD30
Discovery
Preclinical
Phase I
T-cell & Hodgkin's Lymphoma
TUB-010/TEQ102
Detailed Content Here